Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.

AUTOR(ES)

Factor, S A

RESUMO

Sixty-three patients with Parkinson's disease who failed bromocriptine therapy for various reasons were treated in an open-label trial of pergolide. The data were evaluated in a retrospective manner. Forty-six percent had a good response and tolerated the pergolide. A comparison of the outcomes regarding response and toxicity revealed that bromocriptine and pergolide act differently in individual patients. A trial of pergolide in Parkinsonian patients failing bromocriptine therapy may be therapeutically useful.

Documentos Relacionados

• Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.
• Bromocriptine in Parkinson's disease: a study of cardiovascular effects.
• Bromocriptine treatment in Parkinson's disease.
• Mesulergine and pergolide in previously untreated Parkinson's disease.
• Bromocriptine induced impotence in Parkinson's disease.